Synchronous Presence of EGFR, ALK Driver Mutations Along With PD L1 Overexpression in a Resected Early Stage Non-Small Cell Lung Cancer: A Case Report and Review of Literature.

about

Synchronous Presence of EGFR, ALK Driver Mutations Along With PD L1 Overexpression in a Resected Early Stage Non-Small Cell Lung Cancer: A Case Report and Review of Literature.

Item

http://www.wikidata.org/entity/Q55263540

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Synchronous Presence of EGFR, ...... port and Review of Literature.

@en

Synchronous Presence of EGFR, ...... port and Review of Literature.

@nl

type

Item

label

Synchronous Presence of EGFR, ...... port and Review of Literature.

@en

Synchronous Presence of EGFR, ...... port and Review of Literature.

@nl

prefLabel

Synchronous Presence of EGFR, ...... port and Review of Literature.

@en

Synchronous Presence of EGFR, ...... port and Review of Literature.

@nl

P1476

Synchronous Presence of EGFR, ...... port and Review of Literature.

@en

P2093

Adarsh Vennepureddy

http://www.w3.org/2001/XMLSchema#string

Alisa Sokoloff

http://www.w3.org/2001/XMLSchema#string

Nishitha Thumallapally

http://www.w3.org/2001/XMLSchema#string

Sara Parylo

http://www.w3.org/2001/XMLSchema#string

Uroosa Ibrahim

http://www.w3.org/2001/XMLSchema#string

P2860

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study

The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizo

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer.

Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases.

P304

50-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.14740/WJON1090E

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29760833

http://www.w3.org/2001/XMLSchema#string

P921

overexpression

P932

5942208

http://www.w3.org/2001/XMLSchema#string